Differentiation-inducing therapy by agents such as 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] represents a useful approach for the treatment for cancer, including acute myeloid leukemia (AML). Recent studies demonstrated that the combined administration of 1,25-(OH)2D3 and differentiation-enhancing agents could alleviate the side effects of 1,25-(OH)2D3 and improve the rate of long term survival. In this study, we determined the enhancing activities of ceramide derivatives on 1,25-(OH)2D3-induced differentiation of human myeloid leukemia HL-60 cells. Importantly, some of these derivatives-namely, A2, B3, and H9-enhanced the 1,25-(OH)2D3-induced differentiation of HL-60 cells in a concentration-dependent manner. In addition, the morphologic studies using Giemsa staining and flow cytometric analysis demonstrated that the combined treatment of 1,25-(OH)2D3 with one of the three analogues, A2, B3, and H9, directed the HL-60 cells into monocytic lineage, but not into granulocytic lineage. The inhibition studies demonstrated that A2, B3, and H9, enhanced 1,25-(OH)2D3-induced differentiation of HL-60 cells via the PI3-K/PKC/JNK/ERK pathways. The ability of ceramide derivatives to enhance the differentiation-inducing potential of 1,25-(OH)2D3 may contribute to an effective therapy for AML.
- 1,25-Dihydroxyvitamin D
- Ceramide library
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
- Pharmacology, Toxicology and Pharmaceutics(all)